Unique ID issued by UMIN | UMIN000045322 |
---|---|
Receipt number | R000051758 |
Scientific Title | The efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group study |
Date of disclosure of the study information | 2021/09/01 |
Last modified on | 2022/04/12 08:44:31 |
The efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects
The efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects
The efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group study
The efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects
Japan |
Healthy Japanese subjects
Not applicable | Adult |
Others
NO
To verify the efficacy and safety of test food consumption for 12 weeks on the visceral fat in healthy Japanese subjects
Safety,Efficacy
Confirmatory
Pragmatic
Not applicable
1. The measured values of abdominal visceral fat area at 12 weeks after consumption (12w)
1. The amount of change of abdominal visceral fat area between screening (before consumption; Scr) and 12w
2. The measured values in each of the following items at 12w: abdominal subcutaneous fat area, total abdominal fat area, body weight, body mass index (BMI), abdominal circumference, waist circumference, body fat percentage, fat mass, lean body mass, muscle mass, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglyceride (TG), and original questionnaires
3. The amount of change from Scr in each of the following items at 12w: abdominal subcutaneous fat area, total abdominal fat area, body weight, BMI, abdominal circumference, waist circumference, body fat percentage, fat mass, lean body mass, muscle mass, total cholesterol, HDL cholesterol, LDL cholesterol, TG
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
NO
Institution is not considered as adjustment factor.
NO
2
Treatment
Food |
Duration: 12 weeks
Test food: Drink containing beta-hydroxybutyric acid (BHB)
Administration: Drink one bottle after breakfast
* Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
Duration:
Test food: Drink not containing BHB
Administration: Drink one bottle after breakfast
* Daily dose should be taken within the day. If you forget to take the test food, take it as soon as you remember within the day.
20 | years-old | <= |
Not applicable |
Male and Female
1. Japanese
2. Men or women
3. Subjects aged 20 or more
4. Healthy subjects
5. Subjects who are judged as eligible to participate in the study by the physician
6. Subjects whose BMI are 23 kg/m2 or more and less than 30 kg/m2 at Scr
7. Subjects whose the visceral fat area are relatively large
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who use or take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily
5. Subjects who are currently taking medications (including herbal medicines) and supplements
6. Subjects who are allergic to medicines and/or the test food related products
7. Subjects who have exercise habits three times or more per week
8. Subjects who work late-night shifts and the erratic lifestyle (particularly dietary habits)
9. Subjects who are on excessive dietary restriction, such as not eating carbohydrates at all
10. Subjects who are on a diet
11. Subjects who are pregnant, breast-feeding, and planning to become pregnant
12. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
13. Subjects who are judged as ineligible to participate in the study by the physician
40
1st name | Tsuyoshi |
Middle name | |
Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
1st name | Naoko |
Middle name | |
Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
03-3818-0610
nao@orthomedico.jp
ORTHOMEDICO Inc.
OSAKA GAS CO., LTD
Profit organization
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
2021 | Year | 09 | Month | 01 | Day |
Unpublished
44
Completed
2021 | Year | 08 | Month | 25 | Day |
2021 | Year | 08 | Month | 25 | Day |
2021 | Year | 09 | Month | 02 | Day |
2022 | Year | 02 | Month | 13 | Day |
2021 | Year | 08 | Month | 31 | Day |
2022 | Year | 04 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051758